PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Segetis, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

IRRRB Approves Funding for Segetis Commercial Plant - Segetis, Inc, announces Minnesota’s Iron Range Resource and Rehabilitation Board (IRRRB) voted unanimously to approve $21.2 million in funding for Segetis to construct a commercial-scale plant at the Laskin Energy Park in Hoyt Lakes, MN
IRRRB Approves Funding for Segetis Commercial Plant

 

NewswireToday - /newswire/ - Golden Valley, MN, United States, 2014/04/22 - Segetis, Inc, announces Minnesota’s Iron Range Resource and Rehabilitation Board (IRRRB) voted unanimously to approve $21.2 million in funding for Segetis to construct a commercial-scale plant at the Laskin Energy Park in Hoyt Lakes, MN.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Segetis is a leader in creating high performance, sustainable materials reducing the world’s dependence on fossil fuel based petrochemicals. Segetis uses proprietary technology to convert biomass to Levulinic Acid and its derivatives for use in wide market applications including plastics and home cleaning products.

“We are delighted with the support from the State of Minnesota and particularly the IRRRB,” said Atul Thakrar, Segetis President and CEO. “This is the foundational funding for our project which will catalyze a biochemical industry cluster in the Iron Range.”

Andrew Skinner, Segetis VP of Operations, has been working with the IRRRB team for several months in the process of developing this proposal. “This first commercial project is significant to the future growth of Segetis. It will bring sustainable economic benefits to the Iron Range through job creation and use of Minnesota’s renewable resources.”

About Segetis
Segetis (segetis.com) creates high performance, sustainable materials, reducing the world's dependence on fossil fuel based petrochemicals. Our Levulinic Acid based technology platform is positioned for significant global adoption with renewable alternatives that address toxicity issues in everyday items. With our flexible production technology, we have the ability to leverage a wide array of biomass feedstocks to meet the increasing demand for these high performance, healthier, biobased materials.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Segetis, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


IRRRB Approves Funding for Segetis Commercial Plant

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Dorie Yontz - Segetis.com 
763-795-7200 info[.]segetis.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Segetis, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Segetis, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)